, Tracking Stock Market Picks
Enter Symbol:
Auxilium Pharmaceuticals, Inc. (AUXL) [hlAlert]

Mkt Outperform
up 117.99 %

Auxilium Pharmaceuticals, Inc. (AUXL) rated Mkt Outperform with price target $24 by JMP Securities

Posted on: Tuesday,  Oct 22, 2013  8:25 AM ET by JMP Securities

JMP Securities rated Mkt Outperform Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 10/22/2013, when the stock price was $16.73.
Since then, Auxilium Pharmaceuticals, Inc. has gained 117.99% as of 01/29/2015's recent price of $36.47.
If you would have followed this JMP Securities's recommendation on AUXL, you would have gained 117.99% of your investment in 464 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

MP Securities' equity research department provides institutional clients with comprehensive industry knowledge, unique insight and actionable information. JMP's senior research analysts are charged with developing proprietary investment themes, anticipating secular and cyclical changes and producing action-oriented reports. JMP follows companies in six industries that exhibit above-average long-term growth characteristics — Technology, Healthcare, Consumer, Real Estate, Financial Services and Business Services — and produces specialized equity research that enables investors to understand and invest in complicated growth stocks profitably.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/22/2013 8:25 AM Buy
16.73 24.00
as of 12/13/2013
1 Week down  -6.37 %
1 Month up  4.43 %
3 Months up  21.09 %
1 YTD up  21.09 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy